These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31622777)

  • 1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH
    Gasbjerg LS; Hartmann B; Christensen MB; Lanng AR; Vilsbøll T; Jørgensen NR; Holst JJ; Rosenkilde MM; Knop FK
    Bone; 2020 Jan; 130():115079. PubMed ID: 31622777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men.
    Skov-Jeppesen K; Svane MS; Martinussen C; Gabe MBN; Gasbjerg LS; Veedfald S; Bojsen-Møller KN; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    Bone; 2019 Aug; 125():178-185. PubMed ID: 31100534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
    Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
    Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.
    Christensen MB; Lund AB; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
    J Endocr Soc; 2020 Sep; 4(9):bvaa097. PubMed ID: 32904711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.
    Christensen MB; Lund A; Calanna S; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2018 Jan; 103(1):288-294. PubMed ID: 29099978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of endogenous GIP in patients with type 2 diabetes.
    Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
    Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
    Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes.
    Dalsgaard NB; Gasbjerg LS; Helsted MM; Hansen LS; Hansen NL; Skov-Jeppesen K; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
    Bone; 2023 May; 170():116687. PubMed ID: 36754130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH
    Gasbjerg LS; Bari EJ; Stensen S; Hoe B; Lanng AR; Mathiesen DS; Christensen MB; Hartmann B; Holst JJ; Rosenkilde MM; Knop FK
    Diabetes Obes Metab; 2021 Jan; 23(1):68-74. PubMed ID: 32886401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study.
    Skov-Jeppesen K; Veedfald S; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    Bone; 2021 Nov; 152():116065. PubMed ID: 34153529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
    Nissen A; Christensen M; Knop FK; Vilsbøll T; Holst JJ; Hartmann B
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2325-9. PubMed ID: 25144635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
    Asmar M; Asmar A; Simonsen L; Gasbjerg LS; Sparre-Ulrich AH; Rosenkilde MM; Hartmann B; Dela F; Holst JJ; Bülow J
    Diabetes; 2017 Sep; 66(9):2363-2371. PubMed ID: 28667118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.
    Skov-Jeppesen K; Christiansen CB; Hansen LS; Windeløv JA; Hedbäck N; Gasbjerg LS; Hindsø M; Svane MS; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1773-1780. PubMed ID: 38217866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans.
    Krogh LSL; Henriksen K; Stensen S; Skov-Jeppesen K; Bergmann NC; Størling J; Rosenkilde MM; Hartmann B; Holst JJ; Gasbjerg LS; Knop FK
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
    Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
    Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GIP(3-30)NH
    Lynggaard MB; Gasbjerg LS; Christensen MB; Knop FK
    Curr Opin Pharmacol; 2020 Dec; 55():31-40. PubMed ID: 33053504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between Postprandial Gut Hormones and Markers of Bone Remodeling.
    Jensen NW; Clemmensen KKB; Jensen MM; Pedersen H; Færch K; Diaz LJ; Quist JS; Størling J
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Jensen MH; Gabe MBN; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetes; 2019 May; 68(5):906-917. PubMed ID: 30626611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.